These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Koskimaki JE; Karagiannis ED; Rosca EV; Vesuna F; Winnard PT; Raman V; Bhujwalla ZM; Popel AS Neoplasia; 2009 Dec; 11(12):1285-91. PubMed ID: 20019836 [TBL] [Abstract][Full Text] [Related]
3. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534 [TBL] [Abstract][Full Text] [Related]
4. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903 [TBL] [Abstract][Full Text] [Related]
5. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065 [TBL] [Abstract][Full Text] [Related]
6. Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. Rivera CG; Rosca EV; Pandey NB; Koskimaki JE; Bader JS; Popel AS J Med Chem; 2011 Oct; 54(19):6492-500. PubMed ID: 21866962 [TBL] [Abstract][Full Text] [Related]
7. Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer. Rosca EV; Koskimaki JE; Pandey NB; Wolff AC; Popel AS Cancer Biol Ther; 2011 Nov; 12(9):808-17. PubMed ID: 21878750 [TBL] [Abstract][Full Text] [Related]
8. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Liang M; Gao C; Wang Y; Gong W; Fu S; Cui L; Zhou Z; Chu X; Zhang Y; Liu Q; Zhao X; Zhao B; Yang M; Li Z; Yang C; Xie X; Yang Y; Gao C Drug Deliv; 2018 Nov; 25(1):1652-1663. PubMed ID: 30394123 [TBL] [Abstract][Full Text] [Related]
9. FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Valentine A; O'Rourke M; Yakkundi A; Worthington J; Hookham M; Bicknell R; McCarthy HO; McClelland K; McCallum L; Dyer H; McKeen H; Waugh DJ; Roberts J; McGregor J; Cotton G; James I; Harrison T; Hirst DG; Robson T Clin Cancer Res; 2011 Mar; 17(5):1044-56. PubMed ID: 21364036 [TBL] [Abstract][Full Text] [Related]
11. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy. Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804 [TBL] [Abstract][Full Text] [Related]
12. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Osuka S; Takano S; Watanabe S; Ishikawa E; Yamamoto T; Matsumura A Neurol Med Chir (Tokyo); 2012; 52(4):186-93. PubMed ID: 22522328 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model. Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879 [TBL] [Abstract][Full Text] [Related]
14. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Read TA; Farhadi M; Bjerkvig R; Olsen BR; Rokstad AM; Huszthy PC; Vajkoczy P Cancer Res; 2001 Sep; 61(18):6830-7. PubMed ID: 11559558 [TBL] [Abstract][Full Text] [Related]
15. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis. Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323 [TBL] [Abstract][Full Text] [Related]
16. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414 [TBL] [Abstract][Full Text] [Related]
17. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Mishima K; Mazar AP; Gown A; Skelly M; Ji XD; Wang XD; Jones TR; Cavenee WK; Huang HJ Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8484-9. PubMed ID: 10890917 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Bello L; Lucini V; Carrabba G; Giussani C; Machluf M; Pluderi M; Nikas D; Zhang J; Tomei G; Villani RM; Carroll RS; Bikfalvi A; Black PM Cancer Res; 2001 Dec; 61(24):8730-6. PubMed ID: 11751392 [TBL] [Abstract][Full Text] [Related]
19. Arresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma. Aikio M; Alahuhta I; Nurmenniemi S; Suojanen J; Palovuori R; Teppo S; Sorsa T; López-Otín C; Pihlajaniemi T; Salo T; Heljasvaara R; Nyberg P PLoS One; 2012; 7(12):e51044. PubMed ID: 23227231 [TBL] [Abstract][Full Text] [Related]
20. A novel antiangiogenic peptide derived from hepatocyte growth factor inhibits neovascularization in vitro and in vivo. Xu Y; Zhao H; Zheng Y; Gu Q; Ma J; Xu X Mol Vis; 2010 Oct; 16():1982-95. PubMed ID: 21031024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]